Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says

 
• By Jessica Merrill

Eli Lilly & Co. CEO David Ricks highlighted how Medicare drug price negotiation policies are already impacting R&D investment during a J.P. Morgan investor call.

benched players
Lilly said it benched three pipeline drugs due to the IRA • Source: Shutterstock

More from R&D

More from Scrip